AstraZeneca said Thursday that the Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) Advisory Committee concluded that SEROQUEL XR was shown to be effective in MDD as both monotherapy and ...
Sourse: More Info
Thursday, April 9, 2009
AstraZeneca: FDA Concludes Seroquel XR Study >AZN
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment